164 related articles for article (PubMed ID: 23246257)
1. Exploring individual HPV coinfections is essential to predict HPV-vaccination impact on genotype distribution: a model-based approach.
Pons-Salort M; Letort V; Favre M; Heard I; Dervaux B; Opatowski L; Guillemot D
Vaccine; 2013 Feb; 31(8):1238-45. PubMed ID: 23246257
[TBL] [Abstract][Full Text] [Related]
2. Patterns of cervical coinfection with multiple human papilloma virus types in a screening population in Denmark.
Goldman B; Rebolj M; Rygaard C; Preisler S; Ejegod DM; Lynge E; Bonde J
Vaccine; 2013 Mar; 31(12):1604-9. PubMed ID: 23313651
[TBL] [Abstract][Full Text] [Related]
3. Revising ecological assumptions about Human papillomavirus interactions and type replacement.
Murall CL; McCann KS; Bauch CT
J Theor Biol; 2014 Jun; 350():98-109. PubMed ID: 24412334
[TBL] [Abstract][Full Text] [Related]
4. Post hoc analysis of the PATRICIA randomized trial of the efficacy of human papillomavirus type 16 (HPV-16)/HPV-18 AS04-adjuvanted vaccine against incident and persistent infection with nonvaccine oncogenic HPV types using an alternative multiplex type-specific PCR assay for HPV DNA.
Struyf F; Colau B; Wheeler CM; Naud P; Garland S; Quint W; Chow SN; Salmerón J; Lehtinen M; Del Rosario-Raymundo MR; Paavonen J; Teixeira JC; Germar MJ; Peters K; Skinner SR; Limson G; Castellsagué X; Poppe WA; Ramjattan B; Klein TD; Schwarz TF; Chatterjee A; Tjalma WA; Diaz-Mitoma F; Lewis DJ; Harper DM; Molijn A; van Doorn LJ; David MP; Dubin G;
Clin Vaccine Immunol; 2015 Feb; 22(2):235-44. PubMed ID: 25540273
[TBL] [Abstract][Full Text] [Related]
5. Assessing genital human papillomavirus genoprevalence in young Australian women following the introduction of a national vaccination program.
Osborne SL; Tabrizi SN; Brotherton JM; Cornall AM; Wark JD; Wrede CD; Jayasinghe Y; Gertig DM; Pitts MK; Garland SM;
Vaccine; 2015 Jan; 33(1):201-8. PubMed ID: 25444787
[TBL] [Abstract][Full Text] [Related]
6. Cervical Infection With Vaccine-Associated Human Papillomavirus (HPV) Genotypes as a Predictor of Acquisition and Clearance of Other HPV Infections.
Tota JE; Ramanakumar AV; Villa LL; Richardson H; Burchell AN; Coutlée F; Franco EL
J Infect Dis; 2016 Sep; 214(5):676-84. PubMed ID: 27256157
[TBL] [Abstract][Full Text] [Related]
7. Potential overestimation of HPV vaccine impact due to unmasking of non-vaccine types: quantification using a multi-type mathematical model.
Choi YH; Chapman R; Gay N; Jit M
Vaccine; 2012 May; 30(23):3383-8. PubMed ID: 22480925
[TBL] [Abstract][Full Text] [Related]
8. Cervical coinfection with human papillomavirus (HPV) types as a predictor of acquisition and persistence of HPV infection.
Rousseau MC; Pereira JS; Prado JC; Villa LL; Rohan TE; Franco EL
J Infect Dis; 2001 Dec; 184(12):1508-17. PubMed ID: 11740725
[TBL] [Abstract][Full Text] [Related]
9. Vaccination against multiple HPV types.
Elbasha EH; Galvani AP
Math Biosci; 2005 Sep; 197(1):88-117. PubMed ID: 16095627
[TBL] [Abstract][Full Text] [Related]
10. Distribution of human papillomavirus types in anogenital warts of men.
Chan PK; Luk AC; Luk TN; Lee KF; Cheung JL; Ho KM; Lo KK
J Clin Virol; 2009 Feb; 44(2):111-4. PubMed ID: 19097933
[TBL] [Abstract][Full Text] [Related]
11. Epidemiologic approaches to evaluating the potential for human papillomavirus type replacement postvaccination.
Tota JE; Ramanakumar AV; Jiang M; Dillner J; Walter SD; Kaufman JS; Coutlée F; Villa LL; Franco EL
Am J Epidemiol; 2013 Aug; 178(4):625-34. PubMed ID: 23660798
[TBL] [Abstract][Full Text] [Related]
12. Bivalent Vaccine Effectiveness Against Type-Specific HPV Positivity: Evidence for Cross-Protection Against Oncogenic Types Among Dutch STI Clinic Visitors.
Woestenberg PJ; King AJ; van Benthem BHB; Donken R; Leussink S; van der Klis FRM; de Melker HE; van der Sande MAB; Hoebe CJPA; Bogaards JA;
J Infect Dis; 2018 Jan; 217(2):213-222. PubMed ID: 29140439
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of genital HPV infections and HPV serology in adolescent girls, prior to vaccination.
Mollers M; Scherpenisse M; van der Klis FR; King AJ; van Rossum TG; van Logchem EM; Feltkamp MC; Meijer CJ; Snijders PJ; Boot HJ; de Melker HE
Cancer Epidemiol; 2012 Dec; 36(6):519-24. PubMed ID: 22906483
[TBL] [Abstract][Full Text] [Related]
14. Prevalence and genotype distribution of human papillomavirus infection of the cervix in Spain: the CLEOPATRE study.
Castellsagué X; Iftner T; Roura E; Vidart JA; Kjaer SK; Bosch FX; Muñoz N; Palacios S; San Martin Rodriguez M; Serradell L; Torcel-Pagnon L; Cortes J;
J Med Virol; 2012 Jun; 84(6):947-56. PubMed ID: 22499018
[TBL] [Abstract][Full Text] [Related]
15. Determinants of human papillomavirus coinfections among Montreal university students: the influence of behavioral and biologic factors.
Smith MA; Tellier PP; Roger M; Coutlée F; Franco EL; Richardson H
Cancer Epidemiol Biomarkers Prev; 2014 May; 23(5):812-22. PubMed ID: 24569438
[TBL] [Abstract][Full Text] [Related]
16. Impact of human papillomavirus vaccination on racial/ethnic disparities in vaccine-type human papillomavirus prevalence among 14-26 year old females in the U.S.
Hirth J; McGrath CJ; Kuo YF; Rupp RE; Starkey JM; Berenson AB
Vaccine; 2018 Nov; 36(50):7682-7688. PubMed ID: 30377066
[TBL] [Abstract][Full Text] [Related]
17. Vaccine-relevant human papillomavirus (HPV) infections and future acquisition of high-risk HPV types in men.
Rositch AF; Hudgens MG; Backes DM; Moses S; Agot K; Nyagaya E; Snijders PJ; Meijer CJ; Bailey RC; Smith JS
J Infect Dis; 2012 Sep; 206(5):669-77. PubMed ID: 22711906
[TBL] [Abstract][Full Text] [Related]
18. Global stability of equilibria in a two-sex HPV vaccination model.
Elbasha EH
Bull Math Biol; 2008 Apr; 70(3):894-909. PubMed ID: 17999117
[TBL] [Abstract][Full Text] [Related]
19. Frequency and multiplicity of human papillomavirus infection in HIV-1 positive women in Italy.
Garbuglia AR; Piselli P; Lapa D; Sias C; Del Nonno F; Baiocchini A; Cimaglia C; Agresta A; Capobianchi MR
J Clin Virol; 2012 Jun; 54(2):141-6. PubMed ID: 22437054
[TBL] [Abstract][Full Text] [Related]
20. Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: modeling of sustained antibody responses.
David MP; Van Herck K; Hardt K; Tibaldi F; Dubin G; Descamps D; Van Damme P
Gynecol Oncol; 2009 Dec; 115(3 Suppl):S1-6. PubMed ID: 19217149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
